Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Receivables (2022 - 2024)

Whitehawk Therapeutics (WHWK) has disclosed Receivables for 3 consecutive years, with $5.9 million as the latest value for Q4 2024.

  • On a quarterly basis, Receivables rose 7.56% to $5.9 million in Q4 2024 year-over-year; TTM through Dec 2024 was $5.9 million, a 7.56% increase, with the full-year FY2024 number at $5.9 million, up 7.56% from a year prior.
  • Receivables was $5.9 million for Q4 2024 at Whitehawk Therapeutics, down from $6.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $6.5 million in Q3 2024 to a low of $1.9 million in Q4 2022.
  • A 3-year average of $4.4 million and a median of $5.2 million in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: soared 194.74% in 2023, then fell 11.36% in 2024.
  • Whitehawk Therapeutics' Receivables stood at $1.9 million in 2022, then skyrocketed by 194.74% to $5.5 million in 2023, then increased by 7.56% to $5.9 million in 2024.
  • Per Business Quant, the three most recent readings for WHWK's Receivables are $5.9 million (Q4 2024), $6.5 million (Q3 2024), and $5.9 million (Q2 2024).